Table 3.
Therapeutic agents targeting interleukin-1 or interleukin-1 receptor in interventional clinical trials currently recruiting or not yet recruiting. Data acquired from the U.S. National library of medicine (http://clinicaltrials.gov, accessed on 16 January 2019).
| Therapeutic Agent | Therapeutic Strategy | Cancer Type | Clinical Trial Reference (Phase) |
|---|---|---|---|
| Anakinra (Kineret) | Combined with Nab-paclitaxel, Gemcitabine, Cisplatin | Pancreatic cancer | NCT02550327 (1) |
| Alone | Multiple myeloma | NCT03233776 (2) | |
| Canakinumab (Ilaris) | Alone | 1 NSCLC | NCT03447769 (3) |
| Chemotherapeutic cocktail with or without Canakinumab | NSCLC | NCT03631199 (3) | |
| Possible use of Canakinumab with Spartalizumab and LAG525 | 2 TNBC | NCT03742349 (1) | |
| Docetaxel with Canakinumab vs. Docetaxel with placebo | NSCLC | NCT03626545 (3) | |
| Possible use with PDR001 | Colorectal cancer/TNBC/NSCLC | NCT02900664 (1) | |
| Possible use with PDR001, cisplatin, pemetrexed and carboplatin | NSCLC | NCT03064854 (1) | |
| Possible use with PDR001 | Melanoma | NCT03484923 (2) |
1 NSCLC, Non-small cell lung cancer; 2 TNBC, Triple negative breast cancer.